Pharma Horizons: Artificial Intelligence

EPR’s inaugural Pharma Horizons report explores the latest advances in artificial intelligence (AI) and machine learning (ML) for drug development, pharmaceutical manufacturing and quality control.

AI/ML is predicted to be the top technology investment for 60 percent of life sciences companies over the next two years, according to a recent survey¹ from the Pistoia Alliance. Additionally the pharmaceutical AI market is projected to reach $11.8 billion by 2032, driven by its ability to enhance manufacturing, clinical trials, and research & development.

Register now to access this exclusive content as we delve into some of the challenges and opportunities for AI in pharma, with exclusive insight from:

Robert Schrock, Global Head of Process Development, Cell & Gene, Lonza
Anil Kane, Executive Director and Global Head of Technical & Scientific Affairs, Pharma Services, Thermo Fisher Scientific
Terry Ernest, Director of Manufacturing Science and Technology, Almac Pharma Services
Gregory K Webster, Senior Principal Research Scientist in Development Sciences, and Katherine Young, Scientist I Analytical Chemist in Development Sciences, AbbVie Inc
Paul Marshall, Director of Global Regulatory Affairs at Jazz Pharmaceuticals, British Pharmacopoeia Commissioner and Excipients Chair
Dr Hans Eriksson, Chief Medical Officer, Ketabon and HMNC Brain Health

Stay abreast of the latest developments in AI and ML with articles including:

Augmenting clinical trials with AI
Enhancing contamination control methods: how AI is shaping microbiology and QP oversight
Leveraging generative AI in quality control
Exchanging trial and error for transformative technology.